Sensitization to oxaliplatin in HCT116 and HT29 cell lines by metformin and ribavirin and differences in response to mitochondrial glutaminase inhibition
Open accessAbstract
AIM OF STUDY: In the present study, we evaluated the effect of ribavirin and metformin on the sensitivity of oxaliplatin and 5-fluorouracil (5-FU) on colon cancer. MATERIALS AND METHODS: Cell viability of two commercially available colon cancer cell lines (HT29 and HCT116) were analyzed by sulforhodamine B (SRB) assay. RESULTS: A clinically achievable and nontoxic concentration of ribavirin and metformin showed a significant synergistic effect on oxaliplatin in HT29 and HCT116 cell lines. Ribavirin showed a synergistic effect on oxaliplatin in HT29 (R = 2.93, P < 0.001) and HCT116 (R = 1.71, P < 0.001), while only in HT29 metformin synergized with oxaliplatin by 2.66 (± 0.28, P < 0.01). In addition, both cell lines showed significant differences in response to Compound 968, inhibitor of mitochondrial glutaminase activity. CONCLUSION: The data suggested that these cell lines not only turn to metabolic different sustainability process after oxaliplatin treatment but that they also have different basal metabolic requirements of glutamine in vitro which can be exploits in the future for colorectal cancer (CRC) treatment and further studies are required.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Pharmacological inhibition of glutaminase suppresses cell growth and induces apoptosis in human colorectal cancer cell lines.
“Pharmacological inhibition of glutaminase suppressed cell growth and induced apoptosis in human CRC cell lines, thus suggesting that glutaminase may serve as a target for CRC therapy [11,26,31,32].”
From Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer (2020) · cites this paper as [31]
The Results (page not available in our copy) report inhibitory concentrations for Compound 968, a glutaminase inhibitor, in the HT29 and HCT116 colorectal cancer cell lines. This supports an effect on cell survival, but the paper does not report that glutaminase inhibition induced apoptosis; its mention of apoptosis concerns oxaliplatin. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity
Weinberg, F., Hamanaka, R., Wheaton, W. W., Weinberg, S., Joseph, J., Lopez, M., Kalyanaraman, B., Mutlu, G. M., Budinger, G. R. S., & Chandel, N. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003428107 · Cited by 1,742 · see citing works
Glutamine and cancer: cell biology, physiology, and clinical opportunities
Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69600 · Cited by 1,262 · see citing works
Tumor suppressors and cell metabolism: a recipe for cancer growth
Jones, R. G., & Thompson, C. B. (2009) · Genes & Development · doi:10.1101/gad.1756509 · Cited by 1,085 · see citing works
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923 · see citing works
Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Sakai, E., Uchiyama, T., Suzuki, K., Iida, H., Sakamoto, Y., Yoneda, K., et al. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0186 · Cited by 311 · see citing works
Skeen, J. E., Bhaskar, P. T., Chen, C.-C., Chen, W. S., Peng, X.-D., Nogueira, V., Hahn-Windgassen, A., Kiyokawa, H., & Hay, N. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.022 · Cited by 232 · see citing works
Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy
Selvakumaran, M., Amaravadi, R. K., Vasilevskaya, I. A., & O'Dwyer, P. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1542 · Cited by 221 · see citing works
Hosono, K., Endo, H., Takahashi, H., Sugiyama, M., Uchiyama, T., Suzuki, K., Nozaki, Y., Yoneda, K., Fujita, K., Yoneda, M., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20637 · Cited by 177 · see citing works
Use of Antidiabetic Agents and the Risk of Pancreatic Cancer: A Case–Control Analysis
Bodmer, M., Becker, C., Meier, C., Jick, S. S., & Meier, C. R. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2011.483 · Cited by 139 · see citing works
Targeting PI3K Signaling as a Therapeutic Approach for Colorectal Cancer
Zhang, J., Roberts, T. M., & Shivdasani, R. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.05.010 · Cited by 121 · see citing works
Metabolic Enzyme IMPDH Is Also a Transcription Factor Regulated by Cellular State
Kozhevnikova, E. N., van der Knaap, J. A., Pindyurin, A. V., Özgür, Z., van IJcken, W. F. J., Moshkin, Y. M., & Verrijzer, C. P. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.04.030 · Cited by 110 · see citing works
Autophagy Protects against Oxaliplatin-Induced Cell Death via ER Stress and ROS in Caco-2 Cells
Shi, Y., Tang, B., Yu, P.-W., Tang, B., Hao, Y., Lei, X., Luo, H.-X., & Zeng, D.-Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051076 · Cited by 91 · see citing works
Matassa, D. S., Amoroso, M. R., Agliarulo, I., Maddalena, F., Sisinni, L., Paladino, S., Romano, S., Romano, M. F., Sagar, V., Loreni, F., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.379 · Cited by 73 · see citing works
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells
Davidson, D. L., Coulombe, Y., Marignac, V. L. M., Amrein, L., Grenier, J. M., Hodkinson, K., Masson, J., Aloyz, R. S., & Panasci, L. (2011) · Investigational New Drugs · doi:10.1007/s10637-010-9626-9 · Cited by 57 · see citing works
Pharmacological targeting of eIF4E in primary CLL lymphocytes
Marignac, V. L. M., Shawi, M., Carpio, E. P., Wang, X., Panasci, L., Miller, W. H., Pettersson, F., & Aloyz, R. S. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.43 · Cited by 21 · see citing works
Flagged first, then by citations
1 of the 16 references couldn’t be matched to a known paper.
Research works printed but not linked: 15
- Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33.
- Borden KL, Culjkovic-Kraljacic B. Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and beyond? Leuk Lymphoma 2010;51:1805-15.
- Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski LK, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972;177:705-6.
- Yamada Y, Natsumeda Y, Weber G. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. Biochemistry 1988;27:2193-6.
- Collart FR, Chubb CB, Mirkin BL, Huberman E. Increased inosine-5'-phosphate dehydrogenase gene expression in solid tumor tissues and tumor cell lines. Cancer Res 1992;52:5826-8.
- Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014;10:143-56.
- Misset JL, Bleiberg H, Sutherland W, Bekradda M, Cvitkovic E. Oxaliplatin clinical activity: A review. Crit Rev Oncol Hematol 2000;35:75-93.
- Li J, Hou N, Faried A, Tsutsumi S, Kuwano H. Inhibition of autophagy [Downloaded free from http://www.cancerjournal.net on Monday, July 30, 2018, IP: 168.96.240.Journal of Cancer Research and Therapeutics -April-June 2015 -Volume 11 -Issue 2 augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model. Eur J Cancer 2010;46:1900-9.
- Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-6.
- Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 2008;99:2136-41.
- Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011;30:1174-82.
- Chen J, Huang XF, Qiao L, Katsifis A. Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol 2011;2:27-33.
- Vizan P, Alcarraz-Vizan G, Diaz-Moralli S, Solovjeva ON, Frederiks WM, Cascante M. Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 2009;124:2789-96.
- Huang F, Zhang Q, Ma H, Lv Q, Zhang T. Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int J Clin Exp Pathol 2014;7:1093-100.
- Wang J, Kuropatwinski K, Hauser J, Ross MR, Zhou Y, Conway A, et al. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol Cancer Ther 2007;6:1143-50.
Cited by
Sorted by citations
Dysregulation of glutaminase and glutamine synthetase in cancer
Matés, J. M., Campos-Sandoval, J. A., Santos-Jiménez, J. D. L., & Márquez, J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.09.011 · Cited by 197 · see citing works
Metformin in colorectal cancer: molecular mechanism, preclinical and clinical aspects
Kamarudin, M. N. A., Sarker, M. M. R., Zhou, J., & Parhar, I. S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1495-2 · Cited by 190 · see citing works
Mazewski, C., Liang, K., & de Mejı́a, E. G. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.04.038 · Cited by 80 · see citing works
Improved anti-tumor activity of oxaliplatin by encapsulating in anti-DR5 targeted gold nanoparticles
Tummala, S., Kumar, M. N. S., & Pindiprolu, S. K. S. S. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1199606 · Cited by 71 · see citing works
Hoerner, C. R., Chen, V. J., & Fan, A. C. (2019) · Kidney Cancer · doi:10.3233/kca-180043 · Cited by 68 · see citing works
Radiotherapy-triggered reduction of platinum-based chemotherapeutic prodrugs in tumours
Fu, Q., Zhang, S., Shen, S., Gu, Z., Chen, J., Song, D., Sun, P., Wang, C., Guo, Z., Gao, Y. Q., et al. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01239-x · Cited by 63 · see citing works
Song, Z., Wei, B., Lu, C., Li, P., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6538 · Cited by 61 · see citing works
Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic
Volpin, F., Casaos, J., Sesen, J., Mangraviti, A., Choi, J. H., Gorelick, N. L., Frikeche, J., Lott, T., Felder, R., Scotland, S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.457 · Cited by 61 · see citing works
Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments
Tang, Y., Li, D., Duan, J.-Y., Sheng, L., & Wang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i6.926 · Cited by 58 · see citing works
Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer
Cohen, A. S., Geng, L., Zhao, P., Fu, A., Schulte, M. L., Graves-Deal, R., Washington, M. K., Berlin, J., Coffey, R. J., & Manning, H. C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100828 · Cited by 49 · see citing works
“Pharmacological inhibition of glutaminase suppressed cell growth and induced apoptosis in human CRC cell lines, thus suggesting that glutaminase may serve as a target for CRC therapy [11,26,31,32].”
BackgroundKheradmand, F., Mohammadian, M., Zeynali-Moghaddam, S., Azarbayjani, A. F., & Ansari, M. K. (2017) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.217432 · Cited by 44 · see citing works
Jiaojiao, H., Wang, K., Zheng, N., Qiu, Y., Xie, G., Su, M., Jia, W. P., & Li, H. (2015) · Scientific Reports · doi:10.1038/srep17423 · Cited by 43 · see citing works
Neto, J. G. D. O., Filho, J. G. D. S., Bittar, E. M., Silva, L. M., de Sousa, F. F., Domingos, H. V., Costa-Lotufo, L. V., Reis, A. S., & dos Santos, A. O. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111658 · Cited by 38 · see citing works
Vernieri, C., Galli, F., Ferrari, L., Marchetti, P., Lonardi, S., Maiello, E., Iaffaioli, R. V., Zampino, M. G., Zaniboni, A., Placido, S. D., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0442 · Cited by 36 · see citing works
Strategy to targeting the immune resistance and novel therapy in colorectal cancer
Wang, G., Wang, J., Guan, R., Sun, Y., Shi, F., Zhang, J., Li, Z., Gao, J., & Fu, X. (2018) · Cancer Medicine · doi:10.1002/cam4.1386 · Cited by 31 · see citing works
Šalovská, B., Gao, E., Müller‐Dott, S., Li, W., Cordon, C. C., Wang, S., Dugourd, A. J. F., Rosenberger, G., Sáez-Rodríguez, J., & Liu, Y. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1179 · Cited by 28 · see citing works
Arafa, K., Shamma, R. N., El-Gazayerly, O. N., & El-sherbiny, I. M. (2018) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2018.1438463 · Cited by 29 · see citing works
Wang, G., Wang, Y.-Z., Yu, Y., Wang, J., Yin, P., & Xu, K. (2019) · Nutrition and Cancer · doi:10.1080/01635581.2019.1631858 · Cited by 28 · see citing works
Metallodrugs: Synthesis, mechanism of action and nanoencapsulation for targeted chemotherapy
Rodrigues, J. A. O., Kiran, N. S., Chatterjee, A., Prajapati, B. G., Dhas, N. L., dos Santos, A. O., de Sousa, F. F., & Souto, E. B. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116644 · Cited by 29 · see citing works
Ribavirin as a potential therapeutic for atypical teratoid/rhabdoid tumors
Casaos, J., Huq, S., Lott, T., Felder, R., Choi, J. H., Gorelick, N. L., Peters, M., Xia, Y., Maxwell, R., Zhao, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23883 · Cited by 23 · see citing works
Rausch, M., Rutz, A., Allard, P., Delucinge-Vivier, C., Docquier, M., Dormond, O., Dyson, P. J., Wolfender, J., & Nowak-Sliwinska, P. M. (2021) · Cancers · doi:10.3390/cancers13163978 · Cited by 19 · see citing works
Development of biocarrier for violacein controlled release in the treatment of cancer
Berti, I. R., Rodenak‐Kladniew, B., Pérez, A. A., Santiago, L. G., Durán, N., & Castro, G. R. (2019) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2019.01.001 · Cited by 19 · see citing works
Ge, S., Zhang, Q., Chen, Y., Tian, Y., Yang, R., Xu, C., Li, F., & Zhang, B. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115450 · Cited by 19 · see citing works
Yip, K., Tsai, T., Yang, I., Miao, Z., Chen, Y., Li, C., Su, W., Chang, T., Huang, C., Tsai, H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10050955 · Cited by 18 · see citing works
Martišová, A., Sommerová, L., Kuricová, K., Podhorec, J., Vojtěšek, B., Kaňková, K., & Hrstka, R. (2019) · Oncology Letters · doi:10.3892/ol.2019.10800 · Cited by 16 · see citing works
How far along are we in revealing the connection between metformin and colorectal cancer?
Berković, M. C., Mikulić, D., Bilić-Čurčić, I., & Mrzljak, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i14.1362 · Cited by 14 · see citing works
Growth inhibition and transcriptional effects of ribavirin in lymphoma
Domínguez-Gómez, G., Cortez‐Pedroza, D., Chávez-Blanco, A. D., Taja‐Chayeb, L., Hidalgo‐Miranda, A., Cedro‐Tanda, A., Beltrán‐Anaya, F. O., Díaz‐Chávez, J., Schcolnik‐Cabrera, A., González‐Fierro, A., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7240 · Cited by 11 · see citing works
Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma
Hong, S. H., Lee, K. S., Hwang, H.-J., Park, S.-Y., Han, W. K., & Yoon, Y. E. (2022) · Genes · doi:10.3390/genes13071211 · Cited by 9 · see citing works
Cytotoxic Compounds from Wrightia pubescens (R.Br.).
Reyes, M. M. D. L., Oyong, G. G., Ng, V. A. S., Shen, C., & Ragasa, C. Y. (2018) · PubMed Central · doi:10.4103/pr.pr_45_17 · Cited by 9 · see citing works
Targeting Metabolic Pathways in Kidney Cancer
Hoerner, C. R., Miao, S. Y., Hsieh, J. J.-D., & Fan, A. C. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000472 · Cited by 9 · see citing works
The in vitro treatment of mesenchymal stem cells for colorectal cancer cells
Sel, F. A., Erol, A., Süleymanoğlu, M., Demirayak, G., Çınar, Ç. K., Kuruca, S. E., & Oğuz, F. S. (2023) · Medical Oncology · doi:10.1007/s12032-023-01972-4 · Cited by 7 · see citing works
Cytotoxic Prenylflavanones from Philippine Stingless Bee (Tetragonula biroi Friese) Nests
Reyes, M. M. D. L., Oyong, G. G., Ebajo, V. D., Shen, C., & Ragasa, C. Y. (2018) · Asian Journal of Chemistry · doi:10.14233/ajchem.2018.21053 · Cited by 7 · see citing works
Kolour, H. R., Bahrami, N., Mojarad, E. N., Sadeghi, A., Shamsara, M., & Fatemi, N. (2025) · Discover Oncology · doi:10.1007/s12672-025-03905-1 · Cited by 6 · see citing works
Bytautaitė, M., Kitrytė, V., Jonutė, P., Endriulaitytė, U., Petrikaitė, V., & Syrpas, M. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104995 · Cited by 6 · see citing works
Beyond cytotoxic potency: disposition features required to design ADC payload
Sun, H., Wienkers, L. C., & Lee, A. J. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2381139 · Cited by 5 · see citing works
Studies of Malaysian Plants in Prevention and Treatment of Colorectal Cancer
Hashim, Y. Z. H.-Y., Gill, C. I. R., Latimer, C. H., Ternan, N. G., & Abbas, P. (2016) · InTech eBooks · doi:10.5772/62868 · Cited by 4 · see citing works
Therapeutic Targeting of Glutamine Metabolism in Colorectal Cancer
Ratre, Y. K., Verma, H. K., Mehta, A., Soni, V. K., Sonkar, S. C., Shukla, D., Ekka, A., Prajapati, S. K., Mahilkar, S., & Vishvakarma, N. K. (2021) · Springer eBooks · doi:10.1007/978-3-030-64668-4_15 · Cited by 4 · see citing works
Devi, N., Warrier, V. P., & Karunagaran, D. (2024) · Molecular & Cellular Toxicology · doi:10.1007/s13273-024-00488-w · Cited by 2 · see citing works
Al-Keilani, M. S., & Alsmadi, D. H. (2018) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2018v10i1.22947 · Cited by 2 · see citing works
Deep Phosphoproteomic Elucidation of Metformin-Signaling in Heterogenous Colorectal Cancer CellsPreprint
Šalovská, B., Gao, E., Müller‐Dott, S., Li, W., Dugourd, A. J. F., Rosenberger, G., Sáez-Rodríguez, J., & Liu, Y. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.07.499038
Metformin in the prevention and treatment of colorectal cancer
Hromakova, I. А., Сорочан, П. П., Prokhach, N. E., Hromakova, I. S., & Olkhovskyi, D. V. (2025) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.1.2025.82-99
- Authors
- Martinez Marignac, V., & Richard, S.
- Affiliations
- National University of Quilmes (AR)
- Venue
- Journal of Cancer Research and Therapeutics
- Published
- 2015
- Volume
- 11
- Issue
- 2
- Pages
- 336
- ISSN
- 0973-1482 (ISSN-L)
- OpenAlex
- W1698996065
- Cited by
- 42
- References
- 16
- Citations by year
- 2025: 2 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 5 · 2020: 2 · 2019: 8 · 2018: 6 · 2017: 3 · 2016: 3 · 2015: 1
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Journal of Cancer Research and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Americanae (AECID Library) (publishedVersion, other-oa)
- Americanae (AECID Library) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Ministerio de Ciencia, Tecnología e Innovación Productiva
- Universidad de la República Uruguay
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- oxaliplatin, metformin, ribavirin, 5-fluorouracil, colorectal cancer, drug synergy, HCT116 cells, HT-29 cells, glutamine metabolism, chemosensitization
- MeSH terms
- Oxaliplatin, Antineoplastic Agents, Cell Survival, Dose-Response Relationship, Drug, Drug Synergism, Glutaminase, Humans, Metformin, Mitochondria, Organoplatinum Compounds, Ribavirin, HT29 Cells, Inhibitory Concentration 50, HCT116 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
